Literature DB >> 743488

Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring.

P Workman, C R Wiltshire, P N Plowman, N M Bleehen.   

Abstract

Concentrations of misonidazole and its O-demethylated metabolite Ro 05-9963 in the plasma and saliva of 10 patients with malignant disease have been determined. A good linear correlation was established between plasma and saliva misonidazole concentration, and salivary sampling was found to be suitable for the estimation of a number of pharmacokinetic parameters. Data are also presented for serial tumour cencentrations of misonidazole and Ro 05-9963 in 3 of the 10 patients. Monitoring of salivary misonidazole concentration appears to be a useful alternative to plasma monitoring, particularly for those patients in whom plasma sampling is unsuitable or impossible.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 743488      PMCID： PMC2009825          DOI： 10.1038/bjc.1978.277

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  16 in total

1.  [Chemistry of residual saliva of a single salivary gland].

Authors:  A KOSTLIN; S RAUCH
Journal:  Helv Med Acta       Date:  1957-11

2.  Methods for collecting individual components of mixed saliva: the relevance to clinical pharmacology.

Authors:  K W Stephen; C F Speirs
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

3.  Use of saliva in therapeutic drug monitoring.

Authors:  M G Horning; L Brown; J Nowlin; K Lertratanangkoon; P Kellaway; T E Zion
Journal:  Clin Chem       Date:  1977-02       Impact factor: 8.327

Review 4.  Oral absorption and secretion of drugs.

Authors:  C F Speirs
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

5.  Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

Authors:  D Perrier; M Gibaldi
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

6.  Salivary concentrations of antiepileptic drugs.

Authors: 
Journal:  Lancet       Date:  1976-09-18       Impact factor: 79.321

7.  Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography.

Authors:  P Workman; C J Little; T R Marten; A D Dale; R J Ruane; I R Flockhart; N M Bleehen
Journal:  J Chromatogr       Date:  1978-05-01

8.  Clinical studies with misonidazole.

Authors:  C R Wiltshire; P Workman; J V Watson; N M Bleehen
Journal:  Br J Cancer Suppl       Date:  1978-06

9.  Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.

Authors:  R C Urtasun; P Band; J D Chapman; H R Rabin; A F Wilson; C G Fryer
Journal:  Radiology       Date:  1977-03       Impact factor: 11.105

10.  Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.

Authors:  S Dische; M I Saunders; M E Lee; G E Adams; I R Flockhart
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640
View more
  10 in total

1.  Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.

Authors:  P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  A rapid and specific semi-micro method involving high-pressure liquid chromatography for the assay of metronidazole in plasma, saliva, serum, urine and whole blood.

Authors:  C M Kaye; M G Sankey; L A Thomas
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

3.  Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors.

Authors:  P E Noker; L Simpson-Herren; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Structure-pharmacokinetic relationships for misonidazole analogues in mice.

Authors:  P Workman; J M Brown
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring.

Authors:  M R Stratford; M F Dennis; P Hoskin; H Phillips; R J Hodgkiss; A Rojas
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

6.  Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity.

Authors:  P Workman; N M Bleehen; C R Wiltshire
Journal:  Br J Cancer       Date:  1980-02       Impact factor: 7.640

7.  The penetration of misonidazole into spontaneous canine tumours.

Authors:  R A White; P Workman; L N Owen; N M Bleehen
Journal:  Br J Cancer       Date:  1979-08       Impact factor: 7.640

8.  Saliva as a sampling source for the detection of leukemic fusion transcripts.

Authors:  Dongmei Chen; Najie Song; Runfang Ni; Jiangning Zhao; Jiasheng Hu; Quanyi Lu; Qingge Li
Journal:  J Transl Med       Date:  2014-11-19       Impact factor: 5.531

9.  Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.

Authors:  J M Brown; N Y Yu; P Workman
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640

10.  Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.

Authors:  P Workman
Journal:  Br J Cancer       Date:  1979-09       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.